

3/23/99

II 510(k) Summary of Safety and Effectiveness
in Accordance with SMDA'90

P. 1 of 1

B. Braun Medical, Inc
824 Twelfth Avenue
Bethlehem, PA 18018
(610)691-5400

September 28, 1998

K983794

Contact: Mark S. Alsberge, Regulatory Affairs Director

Product Name: Chemo Mini Spike Plus

Trade Name: Chemo Mini Spike Plus

Classification name:

General Hospital
Class II, 80LHI
21 CFR 880.5440

SUBSTANTIAL EQUIVALENCE¹ TO:

510(k) number	Name	Applicant
K925401	I.V. Fluid Transfer Pin	B. Braun Medical Inc.

Device Description:

In accordance with section 510(k) for the Federal Food, Drug, and Cosmetic Act, B. Braun Medical, Inc. intends to introduce into interstate commerce the Chemo Mini Spike Plus which is an IV additive dispensing pin for aspiration from multidose containers or injection into IV systems (IV bag).

¹ The term "substantially equivalent" as use herein is intended to be a determination of substantial equivalence from an FDA -regulatory point of view under the Federal Food, Drug, and Cosmetic Act and relates to the fact that the product can be marketed without premarket approval or reclassification. These products may be considered distinct from a patent point of view. The term "substantially equivalent" is not applicable to and does not diminish any patent claims related to this product or the technology used to manufacture the product.

Material:

The Chemo Mini Spike Plus is composed of materials that have been tested in accordance with the EN Standard 30993 and have been determined to be suitable for the intended use of this product.

K983794
P. 2 of 2

Substantial equivalence:

The Chemo Mini Spike Plus is similar in materials, form and intended use to the I.V. Fluid Transfer Pin currently marketed by B. Braun Medical, Inc. and cleared under K925401. There are no new issues of safety or effectiveness raised by Chemo Mini Spike Plus.

Safety And Effectiveness:

All finished products are tested and must meet all required release specifications before distribution. The array of testing required for release include, but are not limited to; physical testing, visual examination (in process and finished product).

The physical testing is defined by Quality Control Test Procedure documents. These tests are established testing procedures and parameters which conform to the product design specifications.

The testing instruction records for each of the individually required procedures are approved, released, distributed and revised in accordance with document control cGMP's.



MAR 23 1999

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Mark S. Alsberge
Regulatory Affairs Director
B. Braun Medical, Incorporated
901 Marcon Boulevard
Allentown, Pennsylvania 18103-9341

Re: K983794
Trade Name: Chemo Mini Spike Plus
Regulatory Class: II
Product Code: LHI
Dated: February 10, 1999
Received: February 16, 1999

Dear Mr. Alsberge:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of


Page 2 - Mr. Alsberge

the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



for Timothy A. Ulatowski
Director
Division of Dental, Infection Control
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

